Alkermes plc and Collaborators to Present Data From Three Ongoing Clinical Development Programs at Two Major Medical Meetings

Published: Dec 03, 2012

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that data on three of the company’s clinical programs are scheduled to be presented at two upcoming major medical meetings this week. At the Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, Fla., Dec. 2-6, 2012, Alkermes will present pharmacokinetic data on ALKS 9070, a new chemical entity currently in phase 3 development for the treatment of schizophrenia. Results will be shown from a clinical trial supporting the once-monthly dosing regimen for this novel injectable agent. Also at that meeting, positive results will be presented from a phase 1/2 study of ALKS 5461, Alkermes’ novel drug candidate for major depressive disorder (MDD), in patients who have an inadequate response to standard therapies for clinical depression. Data relating to the potential use of ALKS 5461 in the treatment of cocaine dependence will also be presented.

Back to news